<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/63A7C928-3A19-4C14-812F-370961534DAC"><gtr:id>63A7C928-3A19-4C14-812F-370961534DAC</gtr:id><gtr:name>John Innes Centre</gtr:name><gtr:department>Contracts Office</gtr:department><gtr:address><gtr:line1>Norwich Research Park</gtr:line1><gtr:line2>Colney</gtr:line2><gtr:line3>Norwich</gtr:line3><gtr:line4>Norwich</gtr:line4><gtr:postCode>NR4 7UH</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/63A7C928-3A19-4C14-812F-370961534DAC"><gtr:id>63A7C928-3A19-4C14-812F-370961534DAC</gtr:id><gtr:name>John Innes Centre</gtr:name><gtr:address><gtr:line1>Norwich Research Park</gtr:line1><gtr:line2>Colney</gtr:line2><gtr:line3>Norwich</gtr:line3><gtr:line4>Norwich</gtr:line4><gtr:postCode>NR4 7UH</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/74309877-4229-47B6-8199-A4CC49110A03"><gtr:id>74309877-4229-47B6-8199-A4CC49110A03</gtr:id><gtr:firstName>Anthony</gtr:firstName><gtr:surname>Maxwell</gtr:surname><gtr:orcidId>0000-0002-5756-6430</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/FADCCE22-AF79-42F6-9171-C4F02D61D3A8"><gtr:id>FADCCE22-AF79-42F6-9171-C4F02D61D3A8</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>Mark</gtr:otherNames><gtr:surname>Lawson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BBS%2FE%2FJ%2F000CA547"><gtr:id>6329BBD8-CA95-4DBD-B5D9-D82A4FD11503</gtr:id><gtr:title>European Gram Negative Antibacterial Engine</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>BBS/E/J/000CA547</gtr:grantReference><gtr:abstractText>The intensive use and misuse of antibiotics has resulted in antibiotic resistance in essentially all human bacterial pathogens. This is especially true when considering resistant Gram-negative infections where resistance is rising and use of drugs of last resort, such as colistin, is increasing. The New Drugs 4 Bad Bugs (ND4BB) initiative is a series of programmes designed to directly address some of the scientific challenges associated with antibacterial drug discovery and development. The ND4BB ENABLE consortium will meet these challenges by creating and optimising a portfolio of new antibiotics ranging from Hits through Phase 1 clinical studies.
The goals of the ENABLE consortium are to:
1. create a drug discovery platform with the expertise and resource base to prosecute multiple antibacterial programmes in parallel;
2. increase the overall pipeline in the antibacterial area by applying this platform to optimise a variety of antibacterial programmes.
More specifically the key objectives of the consortium are designed to increase the overall pipeline of high quality, novel mode of action medicines to treat serious systemic Gram-negative infections by identifying three antibacterial Leads, two antibacterial Candidates and progressing at least one compound into preclinical and Phase 1 clinical studies. The platform group is made up of academics and SMEs from across Europe with diverse expertise and includes 4 large pharma companies. The consortium will provide a unique opportunity for a productive collaboration between academic researchers and industry.
The role of the JIC group in this consortium is to evaluate compounds from other consortium partners as inhibitors of topoisomerases (DNA gyrase and topo IV) from various Gram-negative bacterial species. Positive compounds will be investigated further in terms of their mechanisms of inhibition and structures of the ligand-target complexes using X-ray crystallography.</gtr:abstractText><gtr:fund><gtr:end>2020-01-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2014-02-01</gtr:start><gtr:type>EXPENDITURE_PROJECTED</gtr:type><gtr:valuePounds>137263</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">BBS/E/J/000CA547</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>